INTRODUCTION
============

Cell growth and proliferation require phospholipids, the major building blocks of membranes, and survival during nutritional deprivation depends on energy stored in the form of triacylglycerols (TAGs). Because phospholipids and TAG share common precursors, cells must spatially and temporarily control the flow of lipids toward growth or storage in a nutrient-dependent manner. The mechanisms responsible for this coordination within the endoplasmic reticulum membrane (ER) network, where lipid synthesis takes place, are poorly understood. Such mechanisms are crucial for proper growth control and metabolic homeostasis in healthy individuals, and their disruption underpins the development of cancer, type 2 diabetes, and obesity.

TAGs, together with esterified sterols, are deposited in ubiquitous organelles---lipid droplets (LDs; [@B52]). During LD biogenesis, cells coordinate synthesis of TAG from glycerol and fatty acids through a series of acylation steps, with the expansion of the emerging LD from the ER membrane. Phosphatidate (PA), a key intermediate in the pathway ([Figure 1A](#F1){ref-type="fig"}), is dephosphorylated to diacylglycerol (DAG) by Mg^2+^-dependent PA phosphatases (PAPs; [@B48]). Subsequent fatty acid acylation of DAG by acyltransferases (DGATs) generates TAG ([@B69]). Because the size and number of LDs vary widely between cell types and growth stage, homeostatic mechanisms coordinating LD biogenesis with nutritional or developmental status must be in place, but these are largely unknown.

![Nutrient-dependent targeting of Pah1 to a subdomain of the nuclear envelope. (A) Schematic of the main lipid biosynthetic pathways that control membrane growth vs. storage. Dashed arrows indicate pathways that channel DAG to phospholipids. The Kennedy pathway directly channels DAG to phospholipids (bottom dashed arrow). (B) Left, growth curve of the cells imaged in C. Optical density (OD~600~) at which growth deceleration and the transitions in Pah1\*-GFP targeting take place. Right, neutral lipid levels during growth. Cells were labeled with BODIPY 493/503, and fluorescence was quantified as described in *Material and Methods*. Data are representative of four independent repeats. (C) Wild-type cells expressing the indicated fusion proteins and labeled with MDH to visualize LDs were grown from exponential phase (Exp) to the indicated densities and imaged live. Arrowheads point to intermediates where Pah1\*-GFP is both on NVJ and LD. Arrows point to Pah1\*-GFP on the nuclear membrane flanking the NVJ at later stages. The star indicates the vacuole, identified by its autofluorescence. (D) Quantification of the Pah1\*-GFP relocalization shown in C. Two hundred cells from three independent experiments were scored. (E) Colocalization of Pah1\*-GFP with Nvj1-mCherry during the exit from exponential growth. Wild-type cells (RS453) expressing a chromosomally integrated Nvj1-mCherry and Pah1\*-GFP were grown as in B and C and imaged at an OD~600~ of 4.1. The outline of the cell is depicted, and the position of the vacuole (vac) indicated. (F) Lipin 2 targets the nuclear membrane--associated LD pool. *pah1*∆ cells expressing lipin2-GFP and the indicated reporters were grown to the post--diauxic shift (PDS) phase and imaged by epifluorescence microscopy using a Zeiss Axioplan microscope. (G) Targeting of Pah1\*-GFP to the nuclear envelope in the *nvj1*Δ mutant. Cells expressing the indicated fusion proteins were grown to an OD~600~ of 7.2 and imaged as in C. Scale bar, 5 μm (C, E--G).](3641fig1){#F1}

PA is also a central precursor for the synthesis of phospholipids. Therefore the PAP reaction is a key branching step that commits glycerol backbones and fatty acids for TAG synthesis. Budding yeast expresses one PAP enzyme that is essential for TAG synthesis, Pah1 ([@B24]), whereas mammals express three PAPs, lipins 1--3 ([@B50]; [@B13]). Rodent models of lipin 1 deficiency display a lipodystrophic phenotype, characterized by significant reduction in fat mass and lack of adipocyte differentiation ([@B8]). Of note, unlike other enzymes of the TAG biosynthetic pathway, Pah1 and lipins lack transmembrane domains and therefore must first translocate onto membranes in order to generate DAG. This step is inhibited by multisite phosphorylation, mediated by Pho85, Cdc28, and protein kinase A in yeast ([@B6], [@B5]; [@B60]) and target of rapamycin (TOR) and mitotic kinases in mammals ([@B28]; [@B25]; [@B22]). Dephosphorylation of Pah1 is catalyzed by the highly conserved transmembrane Nem1-Spo7 complex ([@B58]; [@B54]) and is required for Pah1 membrane recruitment and activation ([@B46]; [@B32]; [@B6]).

Of interest, in addition to their TAG storage defects, *pah1*Δ mutants display a reciprocal increase in membrane biogenesis at the ER that results in a striking expansion of the nuclear membrane, suggesting that Pah1 regulation may be also important for nuclear envelope remodeling ([@B54]; [@B56]). Similar nuclear defects were described in fission yeast cells lacking the Pah1 orthologue Ned1 ([@B61]), whereas a role for lipins in nuclear envelope dynamics and nuclear morphology has been also established in worms and mammals ([@B20]; [@B19]; [@B42]; [@B2]).

Despite the progress on the protein factors that regulate Pah1, the physiological signals that drive this enzyme to its membrane-bound form and the identity of the ER compartment(s) where it is activated have remained elusive. Given the critical position of Pah1 in lipid synthesis, in this study, we set out to test the hypothesis that growth and nutrient signals during starvation control Pah1 targeting to membranes and determine the site where Pah1-mediated lipid partitioning takes place.

RESULTS
=======

Nutritional control of Pah1 targeting mediates LD biogenesis at a nuclear membrane subdomain
--------------------------------------------------------------------------------------------

To test whether Pah1 activation on membranes drives lipid flux toward storage, we first examined targeting of Pah1 in time-course experiments during growth in glucose. Pah1--green fluorescent protein (GFP) detection has been hindered by its low expression levels and protein instability due to proteasome-mediated degradation of the activated enzyme ([@B49]). This prompted us to use a Pah1-GFP fusion carrying the D398A D400A mutations within its DXDX(T/V) catalytic motif (hereafter referred to as Pah1\*-GFP). This mutant binds membranes without dephosphorylating PA ([@B32]) and is more stable than the wild-type enzyme ([@B49]). To avoid the severe effects of loss of Pah1 activity in cell morphology and growth, all experiments using Pah1\*-GFP described here were performed in cells expressing the endogenous Pah1.

During exponential phase and the presence of ample glucose, Pah1\*-GFP exhibits a diffuse cytoplasmic distribution (98 ± 1% cells), consistent with continued phospholipid production for sustaining biomass accumulation. After the deceleration of growth due to glucose exhaustion at the diauxic shift (post--diauxic shift \[PDS\]) phase (see growth curve in [Figure 1B](#F1){ref-type="fig"}), Pah1\*-GFP targeted transiently the nuclear membrane domain that contacts the vacuole (nuclear vacuole junction \[NVJ\]; [Figure 1, C--E](#F1){ref-type="fig"}). Subsequently, Pah1\*-GFP concentrated to two nuclear membrane puncta flanking the NVJ that were in contact with LDs ([Figures 1, C and D](#F1){ref-type="fig"}; Supplemental Figure S1). We observed that Pah1\*-GFP was in contact with the DAG acyltransferase Dga1, but did not entirely colocalize with it (Supplemental Figure S2). During the NVJ-to-LD transition, we noticed a discontinuous thread of Pah1\*-GFP labeling that connected with adjoining LD-associated pools, suggesting that the NVJ pool of Pah1 gradually concentrates in the proximity of LDs ([Figure 1C](#F1){ref-type="fig"}, arrowheads). Of importance, the most significant increase of neutral lipids coincides with the translocation of Pah1\*-GFP to the nuclear membrane--LD interface ([Figure 1, B and C](#F1){ref-type="fig"}). This suggests that a nutrient-sensing signal targets Pah1 to the nuclear membrane, ensuring that lipid intermediates are diverted from phospholipid synthesis into storage lipids. Of interest, murine lipin 2--GFP showed a similar growth-dependent targeting to the nuclear membrane--LD interface when expressed in *pah1*Δ cells ([Figure 1F](#F1){ref-type="fig"}).

The NVJ is established by the physical interaction of Nvj1 (on the perinuclear ER) and Vac8 (on the vacuolar membrane; [@B47]). The only known function of the NVJ is in the piecemeal microautophagy of the nucleus (PMN), where nonessential portions of the nucleus and nuclear membrane are degraded. Evidence for a lipid-remodeling event during PMN is provided by the presence of other lipid metabolic enzymes at the NVJ ([@B37]) and the fact that a liquid disordered microdomain reporter, Vph1-mCherry, is excluded from the NVJ during PMN ([@B63]; [@B10]). We find that Pah1\*-GFP recruitment to the NVJ coincides with the exclusion of Vph1-mCherry in the PDS phase (Supplemental Figure S3). Therefore Pah1 might have a role in lipid remodeling in order to promote PMN.

To determine the role of NVJ in the recruitment of Pah1 to the nuclear envelope, we imaged Pah1\*-GFP in the *nvj1*Δ mutant. We found that when Pah1\*-GFP localizes to the NVJ in wild-type cells (4 \< OD~600~ \< 6), it maintains a diffuse soluble distribution in *nvj1*Δ cells. However, at later stages (6 \< OD~600~ \< 8), Pah1\*-GFP still localized to a punctum onto the nuclear membrane in 88 ± 3% of the *nvj1*Δ cells ([Figure 1G](#F1){ref-type="fig"}). Moreover, at this stage, neutral lipid or TAG levels did not decrease in *nvj1*Δ (Supplemental Figure S4). Thus the targeting of Pah1 to the nuclear membrane and its function in TAG storage do not require the NVJ.

Because Pah1\*-GFP targets the nuclear membrane at the diauxic shift, we tested whether glucose regulates this translocation. Indeed, acute glucose starvation of exponentially growing cells targets Pah1\*-GFP to the NVJ (40 ± 7%). In addition, in 24 ± 6% cells, Pah1\*-GFP associates with punctuate structures, approximately half of which (44 ± 8%) are in contact with LDs ([Figure 2A](#F2){ref-type="fig"}). Thus, in addition to LDs, Pah1\*-GFP may associate with other organelles under these conditions. In many glucose-starved cells, Pah1\*-GFP also targets the autophagosome (Supplemental Figure S5), suggesting a distinct role for Pah1 in macroautophagy, as recently shown for its mammalian orthologue, lipin-1 ([@B71]). Of importance, after glucose starvation, wild-type Pah1-GFP expressed at endogenous levels showed a similar targeting as Pah1\*-GFP ([Figure 2B](#F2){ref-type="fig"}). Consistent with the increased instability of the catalytically active Pah1, fewer cells with membrane-bound Pah1-GFP could be detected (11 ± 7%), and their fluorescence signal was lower than that of Pah1\*-GFP. As expected, no membrane-bound Pah1-GFP was detected in exponential phase (unpublished data). Thus wild-type Pah1-GFP behaves similarly to Pah1\*-GFP in response to glucose depletion and targets the NVJ, LDs, and additional foci.

![Pah1\*-GFP and Pah1-GFP membrane targeting during glucose starvation. (A) Wild-type cells expressing the indicated fusion proteins and growing in the exponential phase were transferred to medium lacking glucose for 1 h and imaged with a Zeiss Axioplan epifluorescence microscope. (B) Top, *pah1*Δ cells expressing *PAH1-GFP* from a centromeric plasmid and *SEC63-*mCherry and growing in the exponential phase were transferred to medium lacking glucose for 30 min and imaged as in A. Cells were stained with MDH to label LDs. Bottom, wild-type cells expressing chromosomally integrated *PAH1-*GFP and *NUP84*-mCherry were subjected to glucose starvation as described. Arrows point to Pah1-GFP puncta in the proximity of LDs; arrowheads point to Pah1-GFP associated with the NVJ. Scale bar, 5 μm.](3641fig2){#F2}

Metabolic activation of Nem1-Spo7 triggers Pah1\*-GFP recruitment to the nuclear membrane
-----------------------------------------------------------------------------------------

Next we investigated the mechanism of Pah1 translocation to the nuclear membrane in response to nutrient starvation and growth phase. Because phosphorylation inhibits Pah1 membrane binding ([@B32]; [@B6]) and Pho85-Pho80 and protein kinase A (PKA), which phosphorylate Pah1 ([@B5]; [@B60]), are controlled by nutrients, we asked whether inactivation of these kinases could target Pah1 to the nuclear membrane in glucose-replete medium. In *pho85*Δ or in cells in which PKA activity was chemically inhibited, Pah1\*-GFP remained soluble in the cytosol during exponential phase ([Figure 3, A and C](#F3){ref-type="fig"}). Msn2-mCherry translocated into the nucleus under these conditions, confirming the loss of PKA activity upon chemical inhibition ([Figure 3B](#F3){ref-type="fig"}). Similarly, Pah1\*-GFP targeting was not compromised in the PDS phase ([Figure 3C](#F3){ref-type="fig"}) in cells lacking *SNF1*, which encodes the yeast AMP-activated serine/threonine protein kinase and plays a major role in glucose derepression ([@B12]). Therefore Pah1\*-GFP targeting does not require the glucose repression machinery.

![Role of Pho85, PKA, or Snf1 in the targeting of Pah1 to the nuclear envelope and LDs during the PDS phase. (A) Wild-type (WT) cells (W303) or PKA-deficient cells carrying mutations in the ATP-binding pockets of the three catalytic subunits of PKA (*TPK1^M164G^ TPK2^M147G^ TPK3^M165G^*; *tpk1/2/3*) that make them sensitive to 1-NM-PP1 were transformed with the indicated reporter constructs. 1-NM-PP1 is a cell-permeable ATP-analogue that inhibits only the modified Tpk subunits ([@B70]). Cells in early exponential phase were treated with 5 μM 1-NM-PP1 for 5 min at 30°C min and immediately mounted for observation. No change in distribution of Pah1\*-GFP was observed. (B) *tpk1/2/3* cells expressing the indicated reporters were treated with or without 1-NM-PP1 as in A. (C) Wild-type, *pho85*∆ or *snf1*∆ deletion mutants expressing the indicated reporters were grown in exponential or PDS phase as described in [Figure 1, B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}, and imaged by epifluorescence microscopy. Scale bar, 5 μm.](3641fig3){#F3}

Because the inhibition of nutrient-activated kinases involved in Pah1 regulation fails to trigger its recruitment under progrowth conditions, we asked whether Pah1 dephosphorylation, which is catalyzed by the conserved Nem1-Spo7 complex ([@B54]), could be the limiting step for recruitment. Of interest, Nem1-Spo7 exhibits optimal activity toward recombinant Pah1 at acidic pH, which is unusual for an ER enzyme with a cytosolic substrate ([@B59]). Because a decrease in glucose levels is accompanied by acidification of the cytosol, reaching pH 5.0 at the PDS phase ([@B45]), we asked whether pH-dependent Pah1 dephosphorylation governs its targeting to the nuclear membrane at the PDS phase. The following data suggest that this is the case. First, endogenously phosphorylated Pah1 purified from *Saccharomyces cerevisiae* was more efficiently dephosphorylated in vitro by Nem1-Spo7 at pH 5.0, as indicated by the faster-migrating band corresponding to dephosphorylated Pah1 ([Figure 4A](#F4){ref-type="fig"}; [@B46]). Second, Pah1\*-GFP targeted the NVJ in *pma1-007* cells---which exhibit decreased activity of the plasma membrane ATPase Pma1, the major regulator of cytosolic pH in yeast---but not in wild-type cells, grown in glucose-rich medium at pH 3.0 for 1 h ([Figure 4, B and C](#F4){ref-type="fig"}). Similarly, Pah1\*-GFP targeted NVJ in cells treated with 100 mM sodium acetate at pH 4.8 but not at pH 7.0 ([Figure 4, D and E](#F4){ref-type="fig"}). Sodium acetate induces weak acid stress at pH values below or near 4.76, the p*K*~a~ of acetate, since a significant amount is protonated and can diffuse into the cytosol ([@B43]). Third, if pH-dependent Nem1-Spo7 activation is the limiting step of Pah1 targeting, then overexpression of Nem1-Spo7 under nutrient-replete conditions should mimic the kinetics of Pah1 membrane recruitment during starvation. We recently showed that Nem1-Spo7 overexpression targets wild-type Pah1-GFP to LDs ([@B31]) but did not investigate early events of this recruitment. Strikingly, after 2 h of growth in galactose media, 47 ± 7% of *GAL-NEM1/SPO7* cells show clear targeting of Pah1-GFP to the NVJ. As the induction persisted, NVJ localization gradually decreased, with many cells showing discontinuous NVJ targeting and concomitant LD enrichment at 3 h of induction ([Figure 5, A and B](#F5){ref-type="fig"}), suggesting that Pah1 moves from NVJ onto LDs.

![Metabolic regulation of Nem1-Spo7 controls Pah1 targeting to the nuclear envelope. (A) pH-dependent dephosphorylation of Pah1 by the Nem1-Spo7 complex. In vitro reactions using purified proteins at the indicated pH were performed as described in *Materials and Methods*. Arrows point to the different Pah1 electrophoretic mobilities. (B) Wild-type or *pma1-007* cells expressing the indicated fusion proteins were transferred to medium at pH 3.0, grown for 1 h and imaged as in [Figure 1C](#F1){ref-type="fig"}. (C) Quantification of the Pah1\*-GFP targeting to the nuclear envelope shown in B. Two hundred cells from two independent experiments were scored. (D) Pah1\*-GFP targets the NVJ in media buffered to pH 4.8. Wild-type cells (RS453) expressing chromosomally integrated Nvj1-mCherry and Pah1\*-GFP were grown to the exponential phase and resuspended in SC medium 2% glucose with 100 mM sodium acetate buffered at pH 4.8 or 7.7, respectively, for 1 h at 30°C before imaging. (E) Quantification of the Pah1\*-GFP targeting in the sodium acetate media shown in [Figure 4D](#F4){ref-type="fig"}. One hundred cells from two independent experiments were scored. Scale bar, 5 μm (B, D).](3641fig4){#F4}

![Dephosphorylation bypasses the metabolic regulation of Pah1 targeting to the nuclear envelope. (A) Sequential targeting of Pah1-GFP to the NVJ and LDs induced by increasing Nem1-Spo7 levels. *pah1*Δ cells expressing the indicated fusion proteins and carrying the *GAL-NEM1* and *GAL-SPO7* plasmids or the corresponding empty vectors were transferred to galactose-containing medium for 2, 3, and 7 h and imaged as described. Arrowheads point to cells where the LD-associated pools of Pah1 are linked with a thin nuclear membrane thread. (B) Quantification of the Pah1-GFP targeting shown in A. Two hundred cells from two independent experiments were scored. (C) Dephosphorylation of Pah1\*-GFP targets the nuclear envelope constitutively in glucose media. Wild-type cells expressing the indicated fusion proteins were imaged in the exponential or PDS phase, respectively, with a Zeiss Axioplan epifluorescence microscope. (D) Overproduction of the catalytically inactive and constitutively nuclear membrane-bound Pah1\*-7A is dominant negative. Serial dilutions of wild-type cells carrying an empty vector or the indicated GAL-inducible *PAH1* constructs were spotted onto synthetic plates supplemented with either glucose (left) or galactose (right) and grown for 1.5 or 3 d, respectively, at 30°C. (E) Wild-type cells expressing the indicated plasmids were labeled with BODIPY 493/503 to visualize LDs. Overexpression of Pah1\*-7A causes a significant decrease in LD number and the appearance of BODIPY-enriched membranes, similar to those described for *pah1*Δ ([@B1]). (F) Cells carrying an *INO1* promoter-lacZ reporter were assayed for β-galactosidase activity as described in *Materials and Methods*. (G) Cells expressing *SEC63-GFP* to depict nuclear/ER membrane morphology were visualized by epifluorescence microscopy. Scale bar, 5 μm (A, C, E, G).](3641fig5){#F5}

Deletion of the C-terminal tail of Pah1\*-GFP, which is required for interaction with Nem1-Spo7 ([@B31]), prevented targeting onto membranes during glucose starvation or the PDS phase (Supplemental Figure S6). Under either of these growth conditions, Nem1-GFP localizes to a punctum in wild-type cells, similar to what was described for Nem1 during exponential phase ([@B1]), but also displayed a nuclear membrane distribution (Supplemental Figure S7).

The requirement of Nem1-Spo7 for Pah1 activation can be bypassed by mutating seven Pah1 phosphorylated residues to alanines (7A mutant; [@B46]; [@B32]; [@B6]). Consistently, Pah1\*-7A-GFP targets the NVJ even in glucose-replete media ([Figure 5C](#F5){ref-type="fig"}). Of importance, this mutant still translocates to perinuclear LDs during the PDS phase ([Figure 5C](#F5){ref-type="fig"}). Therefore increased TAG levels correlate with the concentration of Pah1\*-7A-GFP in contact with LDs. Collectively our results show that Nem1-Spo7 activation drives Pah1 to the NVJ, and this precedes Pah1 localization to LDs for TAG production.

Because constitutive membrane binding of Pah1\*-7A-GFP does not cause a major growth defect in glucose-replete media, PA must be still available for lipid synthesis and/or the endogenous Pah1 must compete with the catalytically dead enzyme. However, overexpression of Pah1\*-7A, but not Pah1\*, causes slow growth, defects in lipid droplet biogenesis, derepression of *INO1* transcription, and nuclear/ER membrane expansion ([Figure 5, D--G](#F5){ref-type="fig"}). These phenotypes are all observed in *pah1*Δ cells, suggesting that excess Pah1\*-7A has a dominant-negative effect by blocking the access of endogenous Pah1 to PA. Indeed, co-overexpression of wild-type Pah1 rescued the slow growth of Pah1\*-7A ([Figure 5D](#F5){ref-type="fig"}), which indicates that these enzymes compete for binding to a common pool of PA at the nuclear membrane.

ER membrane organization is defective in cells lacking LDs in the PDS phase
---------------------------------------------------------------------------

We next asked whether LD formation at the nuclear membrane is required for the targeting of Pah1\*-GFP. Production of neutral lipids, and concomitant biogenesis of LDs, is absent in cells lacking the steryl acyltransferases *ARE1* and *ARE2* and the DAG acyltransferases *DGA1* and *LRO1* ([@B44]; [@B51]). Pah1\*-GFP still targets the nuclear envelope in cells lacking the four acyltransferases (hereafter called 4Δ) at the PDS phase ([Figure 6A](#F6){ref-type="fig"}) and colocalizes with Nem1-tdTomato ([Figure 6, B and C](#F6){ref-type="fig"}). Association of Pah1\*-GFP with Nvj1-mCherry was seen in 26 ± 7% of the cells under these conditions. Of interest, we observed membrane proliferation in 4Δ cells when Pah1\*-GFP targets the nuclear envelope, as visualized by the Sec63 reporter. Both nuclear and peripheral ER membrane organization is affected, leading to severe defects in nuclear shape and cortical ER organization ([Figure 7A](#F7){ref-type="fig"}). These defects are seen in the *dga1Δlro1Δ* double mutant but not in *are1Δare2Δ* in the PDS phase ([Figure 7A](#F7){ref-type="fig"}) and are absent in 4Δ cells in the exponential phase ([@B51]; see [Figure 9C](#F9){ref-type="fig"} later in the article). Thus membrane proliferation is observed only upon Pah1 activation and under conditions that block acylation of DAG. Altered membrane morphology is not due to increased lethality of the 4Δ strain, as cells with nuclear/ER defects do not stain with propidium iodide, even 24 h after the PDS time at which relative viability is similar to that of the wild-type strain (Supplemental Figure S8). These membrane changes were accompanied by significant increases in DAG, ergosterol, fatty acids, and total phospholipids, including phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, and phosphatidylcholine (PC; [Figure 7, B and C](#F7){ref-type="fig"}).

![Membrane targeting of Pah1\*-GFP in the absence of LDs. (A) The quadruple acyltransferase mutant (4Δ) expressing the indicated fusion proteins was grown to the PDS phase and imaged live. (B) Colocalization of Nem1-tdTomato and Pah1\*-GFP in 4Δ cells. Cells were grown to the PDS phase and imaged as in A. (C) Nem1-tdTomato localizes on the nuclear membrane in 4Δ cells at the PDS phase. Scale bar, 5 μm.](3641fig6){#F6}

![Nuclear/ER membrane defects and lipid composition of cells lacking LDs in the PDS phase. (A) Nuclear shape and ER membrane organization in the indicated strains, visualized by an intranuclear (*PUS1-RFP*) or ER reporter (*SEC63-GFP*), respectively. Images were acquired with a Zeiss Axioplan epifluorescence microscope. Scale bar, 5 μm. (B) Neutral lipid composition of the wild-type (BY4742) and the 4Δ strains in the PDS phase. Cells were labeled and lipids were extracted and separated as described in *Materials and Methods*. Each data point represents the mean ± SD of three experiments. Erg, ergosterol; ErgE, ergosterol ester; FA, fatty acid; FEE, fatty ethyl ester; PL, phospholipid; TAG, triacylglycerol. (C) Phospholipid composition of the wild-type (BY4742) and the 4Δ strains in the PDS phase. Cells were labeled and lipids were extracted and separated as described in *Materials and Methods*. Each data point represents the mean ± SD of three experiments. PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine.](3641fig7){#F7}

Lipid metabolism and ER membrane organization are rewired in cells lacking LDs
------------------------------------------------------------------------------

Our data suggest that Pah1 targeting to the nuclear envelope acts as a metabolic switch to divert PA from phospholipids into TAG stored in LDs. In the absence of TAG storage, DAG could be used for phospholipid synthesis and membrane biogenesis, either by the Kennedy pathway or by Dgk1-dependent synthesis of PA ([Figure 8A](#F8){ref-type="fig"}). The rate-limiting step in the Kennedy pathway of PC synthesis is catalyzed by the conserved cholinephosphate cytidylyltransferase Pct1. Deletion of either *DGK1* or, to a lesser degree, *PCT1* restored partially nuclear morphology in 4Δ cells, as visualized by Sec63-GFP, although we noticed that cytoplasmic membrane build-up is still present in 4Δ *dgk1*Δ cells ([Figure 8B](#F8){ref-type="fig"}). To investigate in more detail how lipid metabolism is rewired in the PDS phase in the 4Δ mutant and whether this affects membrane organization, we examined ER membrane morphology at the ultrastructural level in 4Δ, 4Δ *pct1*Δ, and 4Δ *dgk1*Δ mutants. Consistent with the fluorescence data, electron microscopy revealed that ER membrane proliferation in 4Δ cells, which was more evident in the ER subpopulation connecting the nucleus with the plasma membrane--associated cortical ER ("cytoplasmic ER"; [Figure 8, C and D](#F8){ref-type="fig"}). This was decreased modestly by deletion of *PCT1*. Deletion of *DGK1* rescued both cytoplasmic and cortical ER expansion almost back to wild-type levels ([Figure 8, C and D](#F8){ref-type="fig"}). We noticed that the ER morphology is reorganized in this mutant, with a striking appearance of cytoplasmic ER agglomerates ([Figure 8, C and D](#F8){ref-type="fig"}). We also noticed fragmented ER and giant mitochondria in 17 ± 4% and 18 ± 5% of 4Δ *dgk1*Δ cells, respectively. Of importance, DAG levels increased significantly in 4Δ *dgk1*Δ compared with 4Δ, suggesting that Dgk1 is indeed active in converting DAG to PA in the 4Δ cells ([Figure 8E](#F8){ref-type="fig"}). However, total phospholipids showed, surprisingly, a further increase in 4Δ *dgk1*Δ when compared with the 4Δ cells. This suggests that another phospholipid biosynthetic pathway is up-regulated in the 4Δ *dgk1*Δ cells to detoxify DAG and could be responsible for the accumulation of the ER agglomerates seen in this mutant. Therefore we blocked the PC branch of the Kennedy pathway by generating a 4Δ *dgk1*Δ *pct1*Δ sextuple mutant complemented with a *URA3*-based *DGK1* plasmid and monitored the ability of cells to recover after the PDS phase in the absence of *DGK1*. As seen in [Figure 8F](#F8){ref-type="fig"}, deletion of *PCT1* in the 4Δ *dgk1*Δ mutant results in potent growth inhibition. Therefore, in the absence of TAG synthesis, both Dgk1- and Pct1-dependent pathways are required for membrane homeostasis and viability.

![Role of phospholipid biosynthetic pathways in ER membrane remodeling in cells lacking LDs. (A) Schematic of the roles of Pct1 and Dgk1 in phospholipid synthesis. (B) Nuclear shape defects in the 4Δ mutant are partially rescued by deletion of *DGK1* or *PCT1*. The indicated strains expressing a *SEC63-GFP* were imaged at the PDS phase with a Zeiss Axioplan epifluorescence microscope. Arrows point to round nuclei; arrowheads point to bright, Sec63-GFP--positive spots in the cytoplasm. Percentage of cells with round nuclei. At least 200 cells/strain from two independent experiments were scored. Bar, 5 μm. (C) Electron microscopy analyses. Wild-type (1), 4Δ (2), 4Δ *pct1*Δ (3), and 4Δ *dgk1*Δ (4) cells were grown to the PDS phase before processing for electron microscopy. White squares in 4 delimitate the insets that contain typical examples of ER agglomerates and are shown in 5 and 6 at higher magnification. CW, cell wall; ER, endoplasmic reticulum; LD, lipid droplet; M, mitochondrion; N, nucleus; PM, plasma membrane; V, vacuole. Scale bar, 1 μm; inset, 500 nm. (D) Quantification of the ER membrane expansion shown in C was performed as described in *Materials and Methods*. (E) Neutral lipid composition of the indicated strains in the PDS phase. Cells were labeled and lipids were extracted and separated as described in *Materials and Methods*. Each data point represents mean ± SD of three experiments. Erg, ergosterol; FA, fatty acid; FEE, fatty ethyl ester; PL, phospholipid. (F) Loss of *PCT1* and *DGK1* in the 4Δ strain inhibits growth. The indicated strains expressing a pURA-*DGK1* plasmid were grown to the PDS phase before spotted on complete synthetic plates (SC) without or with 5-fluoroorotic acid (5-FOA). Cells were grown for 2 or 3 d, respectively, at 30°C.](3641fig8){#F8}

Regulation of Pct1 targeting to the nuclear membrane by growth phase
--------------------------------------------------------------------

Pct1 is a soluble enzyme that is activated upon membrane binding ([@B7]) and in yeast interacts with the karyopherin Kap60, which mediates nuclear import ([@B41]). Of interest, in exponentially growing wild-type cells, Pct1 is found exclusively on the nuclear membrane, but in the PDS phase, it is released from membranes and localizes into the nucleus ([Figure 9, A and C](#F9){ref-type="fig"}). Release of Pct1 from the nuclear membrane takes place at the diauxic shift, coinciding with the recruitment of Pah1 ([Figure 9A](#F9){ref-type="fig"}); it is also induced by glucose starvation, indicating that it is regulated by nutrient signals in a manner opposite to that of Pah1 ([Figure 9B](#F9){ref-type="fig"}). Of importance, Pct1 remained bound to the nuclear membrane of 4Δ cells in the PDS phase, when nuclear shape was deformed ([Figure 9, C and D](#F9){ref-type="fig"}). Expression of Dga1, which acylates DAG, restored LD formation, nuclear shape, and the concomitant release of Pct1 from the nuclear membrane into the nucleus in 4Δ ([Figure 9E](#F9){ref-type="fig"}). Thus, channeling DAG to LDs at the nuclear envelope regulates membrane biogenesis. Overexpression of Nem1-Spo7, which targets Pah1 to the nuclear membrane and results in LD formation, also led to an increase in the intranuclear pool of Pct1 (Supplemental Figure S9). Of interest, Pah1 and Pct1 are amphitropic proteins that are recruited to the nuclear membrane via amphipathic helices in a phosphorylation-dependent mechanism. Therefore reversible targeting of soluble enzymes may govern lipid homeostasis in response to changing growth conditions.

![Membrane targeting of Pct1 is regulated in a growth- and nutrient-dependent manner. (A) Wild-type cells (BY4742) expressing chromosomally integrated *PCT1-Cherry* and Pah1\*-GFP were grown to the indicated densities and imaged as in [Figure 1C](#F1){ref-type="fig"}. (B) Wild-type cells (BY4742) expressing a chromosomally integrated *PCT1-GFP* and *SEC63-mCherry* growing in the exponential phase were transferred to medium lacking glucose for 30 min and imaged by epifluorescence microscopy, using a Zeiss Axioplan microscope. (C) Pct1-GFP localization in the presence or absence of LDs at the indicated growth phases. (D) Quantification of the Pct1-GFP relocalization shown in [Figure 7C](#F7){ref-type="fig"} in wild-type and 4Δ cells. Two hundred cells per strain and condition from three independent experiments were scored. (E) DAG channeling to LDs restores nuclear shape in 4Δ cells. The 4Δ mutant expressing the indicated plasmids and *PCT1-mCherry* were grown to the PDS phase, and LDs were visualized using MDH labeling. The outlines of cells are shown in the merged images. Scale bar, 5 μm (A--C, E).](3641fig9){#F9}

DISCUSSION
==========

All cells must continuously balance the flux of lipid metabolites between membranes for growth or storage for survival during nutrient deprivation. Addressing the mechanisms of this regulation is critical for a better understanding of prevalent metabolic diseases such as diabetes or obesity, as well as of cancer, which is characterized by a high demand of lipid synthesis to support cell proliferation. The data presented here provide evidence that compartmentalized activity of Pah1 at the nuclear membrane acts as a switch that controls the balance between membrane and storage lipids.

Despite its central role in lipid metabolism, Pah1 shows a predominantly soluble distribution, reflecting its highly dynamic association with membranes. Addressing its regulation is further complicated by the fact that Pah1 is unstable when activated by Nem1-Spo7 dephosphorylation due to proteasomal degradation ([@B27]). To overcome these problems, we used a catalytically dead Pah1 mutant (Pah1\*) that is partially stabilized ([@B49]) and can be detected on membranes ([@B32]). Although we cannot exclude that interfering with Pah1 stability might affect its localization, the fact that wild-type Pah1 responds to both glucose starvation and Nem1-Spo7 overexpression by targeting the same compartments as Pah1\* suggests that the latter is a physiologically relevant reporter for the localization of Pah1. In addition, wild-type mouse lipin2 also targets LDs during the PDS phase, indicating that at least some aspects of this nutrient-dependent regulation are evolutionarily conserved.

When yeast cells exit exponential growth, they accumulate TAG, which can be used for survival during lengthy starvation periods ([@B35]). Under these conditions, Pah1 targets a punctum on the nuclear membrane that contacts LDs. Of interest, at the same time point, the DAG acyltransferase Dga1 localizes on the LD surface. Therefore, if Pah1-generated DAG at the nuclear membrane is acylated to form TAG, some channeling event is likely to be required to transfer DAG to the growing LD. It is possible that a pool of Pah1 is also present on LDs but not readily detectable by our imaging conditions, although a recent high-confidence proteomic analysis did not identify Pah1 within the LD protein inventory ([@B9]). Alternatively, DAG in close proximity to the forming LD might perform a structural role during the emergence or expansion of LDs from the phospholipid bilayer, as proposed previously ([@B1]).

Remarkably, Pah1 and associated LDs concentrate at the nuclear envelope flanking the NVJ. It is conceivable that such an arrangement facilitates the passage of LDs to the vacuole through the NVJ contacts at later stages of the stationary phase, when LDs are degraded by lipophagy ([@B66]). Because Pah1 targets initially the NVJ at the diauxic shift, it is possible that the same enzyme pool concentrates subsequently to the flanking LD-associated sites. However, because Pah1 still localizes to a punctum at the nuclear membrane in *nvj1*Δ and TAG levels do not decrease in these cells, nuclear--vacuole contacts are not required for the targeting and function of Pah1 in TAG synthesis. Thus Pah1 may perform a distinct role at the NVJ. The NVJ mediates the microautophagic degradation of the nuclear membrane (PMN), which, similar to LD biogenesis, is induced by nutrient depletion and gradually builds up as cells exit the exponential phase. Other lipid metabolic enzymes also concentrate to the NVJ and are required for PMN ([@B34]; [@B38]; [@B37]). Pah1 might thus temporarily coordinate PMN with LD biogenesis, two pathways of membrane lipid recycling that are induced by starvation. Alternatively, Pah1 might control another lipid transport step between the vacuole and the ER that needs to be coordinated with storage in LDs. Because the vacuole contains significant amount of lipids, their export through the NVJ and subsequent storage to the adjacent LDs could require Pah1, although this remains a speculation.

According to the electrostatic/hydrogen bond-switch mechanism, the ionization state of the PA head group is critical for its interaction with effector proteins ([@B36]). Factors like intracellular pH or local membrane environment can influence the charge of PA and thus its ability to interact with soluble proteins. Recent work suggests that mammalian lipins bind PA in vitro by the electrostatic hydrogen bond switch mechanism ([@B15], [@B16]). Cytosolic acidification, which takes place during starvation in yeast, will cause protonation of the PA head group and decreased interaction with PA-binding proteins ([@B55]). However, Pah1 targets membranes and LDs in response to acidification ([Figure 4](#F4){ref-type="fig"}) and starvation ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) in vivo and is required for TAG synthesis in stationary phase ([@B24]). That the NVJ and LD targeting of Pah1 during starvation requires binding to Nem1-Spo7 (Supplemental Figure S6) and Nem1-Spo7 activity in vitro has a pH optimum of 5.0 ([@B59]; [Figure 4A](#F4){ref-type="fig"}) suggests that Nem1-Spo7 is critical for the growth phase-dependent activation of Pah1, although under these conditions, its PA substrate is protonated. Of interest, Nem1-Spo7 is regulated by TOR ([@B14]), and a recent study demonstrated that glucose starvation--dependent TOR activation is governed by cytosolic acidification ([@B11]), suggesting a possible link between growth-dependent pH and Nem1-Spo7 activity. Alternatively, acidification might also control Nem1-Spo7 function more directly. Future work will be needed to address these mechanisms.

Our data suggest that Dgk1 is active in 4Δ cells, converting DAG to PA, which could then be rerouted toward phospholipids and membrane biogenesis. Indeed, a role for Dgk1 in PA-mediated phospholipid synthesis has been described ([@B17]). The facts that in the 4Δ *dgk1*Δ mutant, 1) phospholipids further increased compared with 4Δ, 2) cytoplasmic ER membrane agglomerates accumulated, and 3) ER membrane proliferation and nuclear shape defects were rescued point to a specific role of Dgk1 in channeling PA-derived phospholipids to the nuclear/ER membrane. Consistent with this, overexpression of Dgk1 activity leads to nuclear/ER membrane expansion ([@B23]). In the absence of Dgk1, the Kennedy pathway might channel high DAG levels toward phospholipids. Previous work supports the notion that DAG produced by Pah1 can be redirected toward phospholipids via the Kennedy pathway: overexpression of a constitutively active Pah1 is toxic to cells but can be partially rescued by the supplementation of choline ([@B6]). The function of Dgk1 and Pct1 in maintaining DAG homeostasis is underscored by the strong growth inhibition of the 4Δ *dgk1*Δ *pct1*Δ mutant.

Loss of Pah1 and Nem1-Spo7 results in nuclear structure defects, characterized by a striking expansion of the nuclear and the ER membrane ([@B58]; [@B54]). In *spo7*Δ cells, and presumably *pah1*Δ, this expansion takes place at the membrane adjacent to the nucleolus ([@B4]). The nucleolus is frequently, although not always, associated with the nuclear membrane in contact with the vacuole ([@B37]). The special properties of this domain, characterized as a "membrane sink" ([@B68]), could be due to the localized partitioning of glycerol backbones and fatty acids from membrane phospholipids to TAG in the nuclear envelope--associated LDs. Although the source of fatty acids that acylate DAG during nutrient depletion is unknown, phospholipid deacylation would be a prime candidate. Of interest, Lro1, which catalyzes the direct transfer of fatty acids from phospholipids to DAG, also relocalizes to a specific nuclear envelope domain during the PDS phase ([@B65]). We hypothesize that such interconversion not only might contribute to metabolic homeostasis during growth, also but might also be used for the control of nuclear structure when membrane needs to be added or removed from the nuclear envelope. Because the ER network is in contact with virtually most organelles, it is tempting to speculate that the positioning of LDs, which in yeast remain associated with the ER throughout their life cycle, may be relevant for local membrane- and organelle-remodeling events.

MATERIALS AND METHODS
=====================

Yeast strains and plasmids
--------------------------

Yeast strains are listed in [Table 1](#T1){ref-type="table"}. Gene deletions and epitope tagging by chromosomal integration were generated by a one-step PCR-based method ([@B39]; [@B30]) and confirmed by PCR. Plasmids are listed in [Table 2](#T2){ref-type="table"}.

###### 

Yeast strains used in this work.

  Strain     Genotype                                                                                                  Source/reference
  ---------- --------------------------------------------------------------------------------------------------------- ------------------------------------------
  RS453      *MATα ade2-1 his3-11,15 ura3-52 leu2-3112 trp1-1*                                                         [@B67])
  SS2012     RS453 *URA3::SEC63-mCherry*                                                                               This study
  SS2289     RS453 *nvj1*::*HIS3MX6*                                                                                   This study
  SS2110     RS453 *nvj1*::*KanMX URA3::SEC63-mCherry*                                                                 This study
  SS1991     RS453 *pah1::TRP1 NUP84-mCherry::KanMX*                                                                   This study
  SS2017     RS453 *pah1::TRP1 ERG6-mCherry::KanMX*                                                                    This study
  SS1960     RS453 *nem1::HIS3*                                                                                        [@B58])
  SS1744     RS453 *ERG6-mCherry::KanMX*                                                                               This study
  SS1387     RS453 *PAH1-GFP::KanMX*                                                                                   This study
  SS2435     SS2012 *brp1::KanMX* (aka pma1-007)                                                                       This study
  SS2502     RS453 *NEM1-tdTOMATO::hphNT1*                                                                             This study
  SS2431     RS453 *VPH1-mCherry::KanMX*                                                                               This study
  SS2512     RSY3077 *NEM1-tdTOMATO::hphNT1*                                                                           This study
  SS2014     RS453 *URA3:: NVJ1-mCherry*                                                                               This study
  BY4742     *MATα his3*Δ*1 leu2*Δ*0 lys2*Δ*0 ura3*Δ*0*                                                                Open Biosystems
  RSY3077    *MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 met15Δ0 are1::KanMX are2:KanMX trp1::URA lro1::TRP dga1::Lox-HIS-Lox*   [@B29])
  RSY3018    *MATα his3∆1 leu2∆0 lys2∆0 ura3∆0 met15∆0 are1::KanMX are2:KanMX trp1::URA3*                              Roger Schneiter (University of Fribourg)
  RSY3290    *MATα his3∆1 leu2∆0 lys2∆0 ura3∆0 lro1::KanMX dga1::lox-HIS-lox*                                          Roger Schneiter (University of Fribourg)
  SS2437     RSY3077 *pct1::HIS3MX6*                                                                                   This study
  SS2468     RSY3077 *dgk1::HIS3MX6*                                                                                   This study
  SS2531     SS2468 *pct1::NatMX6* YCplac33-*DGK1*                                                                     This study
  SS2453     BY4742 *PCT1-GFP::HIS3MX6*                                                                                This study
  SS2455     RSY3077 *PCT1-GFP::HIS3MX6*                                                                               This study
  SS2449     BY4742 *PCT1-mCherry::HIS3MX6*                                                                            This study
  SS2452     RSY3077 *PCT1-mCherry::HIS3MX6*                                                                           This study
  W303-1B    *MATα leu2-3112 ura3-1 his3-11,15 trp1-1 ade2-1 can1-100*                                                 [@B62])
  Y3527      W303-1B *tpk1*^M164G^*tpk2*^M147G^*tpk3*^M165G^                                                           [@B70])
  BY4741     *MATa his3∆0 leu2∆0 met15∆0 ura3∆0*                                                                       Open Biosystems
  *pho85*Δ   BY4741 *pho85::KanMX*                                                                                     Open Biosystems
  *snf1*Δ    BY4741 *snf1::KanMX*                                                                                      Open Biosystems

###### 

Plasmids used in this work.

  Plasmid                                  Description                                                                           Source/reference
  ---------------------------------------- ------------------------------------------------------------------------------------- ------------------
  YCplac111-*PAH1-D398A/D400A-GFP*         *PAH1-D398A/D400A-GFP* under control of *PAH1* promoter in *CEN/LEU2* vector          [@B32])
  pAS211-*GAL1/10-NEM1*                    *NEM1* under control of *GAL1/10* promoter in *CEN/ADE2* vector                       [@B31])
  pRS313-*GAL1/10-SPO7*                    *SPO7* under control of *GAL1/10* promoter in *CEN/HIS3* vector                       [@B31])
  YCplac111-*PAH1-D398A/D400A-7A-GFP*      *PAH1-D398A/D400A-7A-GFP* under control of *PAH1* promoter in *CEN/LEU2* vector       This study
  YCplac33-*GAL1/10-PAH1-D398A/D400A-7A*   *PAH1-D398A/D400A-7A* under control of *GAL1/10* promoter in *CEN/URA3* vector        This study
  YEplac181-*GAL1/10-PAH1*                 *PAH1* under control of *GAL1/10* promoter in *2μ/LEU2* vector                        [@B46])
  YEplac181-*GAL1/10-PAH1-D398A/D400A*     *PAH1-D398A/D400A* under control of *GAL1/10* promoter in *CEN/LEU2* vector           This study
  YCplac33-*SEC63-mCherry*                 *SEC63-mCherry* under control of *SEC63* promoter in *CEN/URA3* vector                This study
  YCplac111-*SEC63-GFP*                    *SEC63-GFP* under control of *SEC63* promoter in *CEN/LEU2* vector                    [@B54])
  pRS313-*PUS1-RFP*                        *PUS1-RFP* under control of *PUS1* promoter in *CEN/HIS3* vector                      [@B23])
  YEplac111-*Lipin2-GFP*                   *Lipin2-GFP* under control of *PAH1* promoter in *2μ/LEU2* vector                     This study
  pCumCheV5Atg8416                         *ATG8*-mCherry under control of *CUP1* promoter in *CEN/URA3* plasmid                 This study
  YCplac33-*MSN2-mCherry*                  *MSN2-mCherry* under control of *MSN2* promoter in *CEN/URA3* vector                  This study
  YCplac111-*PAH1-D398A/D400A-Δ837-GFP*    *PAH1-D398A/D400A-Δ837-GFP* under control of *PAH1* promoter into *CEN/LEU2* vector   This study
  YCplac111-*NUP84*-*mCherry*              *NUP84-mCherry* under control of *NUP84* promoter in *CEN/LEU2* vector                This study
  YCplac33-*DGA1-mCherry*                  *DGA1-mCherry* under control of *DGA1* promoter in *CEN/URA3* vector                  This study
  YCplac22-pCup1-*NEM1*                    *NEM1* under control of *CUP1* promoter in *CEN/TRP1* vector                          This study
  YCplac33-pCup1-*SPO7*                    *SPO7* under control of *CUP1* promoter in *CEN/URA3* vector                          This study
  YCplac111-*NEM1-GFP*                     *NEM1-GFP* under control of *NEM1* promoter in *CEN/LEU2* vector                      This study
  pUC-*NEM1-tdTomato*                      *NEM1-tdTomato* hygromycin knock-in construct                                         [@B1])

Media and growth conditions
---------------------------

Unless stated otherwise, all reagents were purchased from Sigma (St. Louis, MO). Cells were transformed using the lithium acetate method. Yeast cells were grown in synthetic medium (SC) containing 2% glucose, 0.2% yeast nitrogen base (Difco, BD, Franklin Lakes, NJ), 0.6% ammonium sulfate, and amino acid drop-out (60 mg/l leucine, 55 mg/l adenine, 55 mg/l uracil, 55 mg/l tyrosine, 20 mg/l arginine, 10 mg/l histidine, 60 mg/l isoleucine, 40 mg/l lysine, 60 mg/l phenylalanine, 50 mg/l threonine, 10 mg/l methionine, 40 mg/l tryptophan) lacking the appropriate amino acids for plasmid selection. For time-course growth experiments, cells were grown overnight at 30°C to the indicated optical densities. For *GAL1/10* promoter--mediated overexpression, cells were initially pregrown in 2% glucose SC medium and then grown overnight in 2% raffinose SC medium, followed by transfer to SC medium containing 2% galactose to a final OD~600~ of 0.2 and incubation at 30°C for the indicated times. For *CUP1* promoter--mediated overexpression, cells were grown in copper-free medium (20 g/l glucose, 5 g/l ammonium sulfate, 1 g/l potassium phosphate, 0.5 g/l magnesium sulfate, 0.1 g/l sodium chloride, 0.1 g/l calcium chloride, 0.5 mg/l boric acid, 0.1 mg/l potassium iodide, 0.2 mg/l ferric chloride, 0.4 mg/l manganese sulfate, 0.2 mg/l sodium molybdate, 0.4 mg/l zinc sulfate, 2 μg/l biotin, 400 μg/l calcium pantothenate, 2 μg/l folic acid, 400 μg/l niacin, 200 μg/l *p*-aminobenzoic acid, 400 μg/l pyridoxine hydrochloride, 200 μg/l riboflavin, 400 μg/l thiamine hydrochloride, and amino acid drop-out lacking the appropriate amino acids for plasmid selection) and incubated with 0.5 mM CuSO~4~ for the indicated times.

For growth assays on plates, yeast cells were grown in the corresponding SC liquid medium with the appropriate carbon source to early logarithmic phase. Ten microliters of serial 10-fold dilutions was spotted onto the appropriate SC plates and incubated at 30°C for 2--4 d. For PKA inactivation experiments, 5 μM C3-1′-naphthyl-methyl PP1 (1NM-PP1; Calbiochem Merck Millipore, Billerica, MA) was added to cells in exponential phase (OD~600~ of ∼0.5) and incubated at 30°C for the indicated times.

Fluorescence microscopy
-----------------------

Cells were grown at 30°C in synthetic medium, pelleted at the appropriate density, and immediately imaged live at room temperature. For imaging, we used two microscopes; for most experiments, we used a Zeiss AxioImager epifluorescence upright microscope with a 100× Plan-Apochromatic 1.4 numerical aperture (NA) objective lens (Carl Zeiss, Jena, Germany). Images were recorded using a large chip sCMOS mono camera for sensitive fluorescence imaging (ORCA Flash 4, version 2; Hamamatsu, Hamamatsu, Japan). Raw image files were saved by Zeiss ZEN blue software and exported to Photoshop (Adobe, San Jose, CA). Where indicated, images were acquired using a Zeiss Axioplan epifluorescence microscope and a 100× Plan-Apochromatic 1.4 NA objective lens connected to a Hamamatsu ORCA R2 charge-coupled device camera. Raw files were saved by Simple PCI6 software (Hamamatsu) and exported to Photoshop. For lipid droplet labeling, cells were stained for 10 min with 1.25 μg/ml BODIPY 493/503 (D-3922; Invitrogen, Carlsbad, CA) or 10 μM monodansylpentane (MDH; SM1000a; Abgent, San Diego, CA) at room temperature. For propidium iodide staining, cells were incubated with 20 μg/ml propidium iodide for 10 min in the dark.

All microscopy images were captured blindly. Quantification was performed on fields obtained from independent experiments. Quantification of Pct1-GFP localization was performed using ImageJ. A line across the nucleus was drawn, and pixel intensity was plotted for Pct1-GFP and Sec63-mCherry, using a 5-pixel average width. Cells were scored for intranuclear localization when mean *PCT1-GFP* pixel intensity increased between Sec63-mCherry maximal pixel intensities.

For three-dimensional (3D) analysis, through-focus image series were acquired on an AxioImagerZ2 fluorescence microscope (Zeiss) using Zen Blue 2012 software (Zeiss). Image series were subsequently deconvolved with Volocity 6.3 (PerkinElmer, Waltham, MA) using calculated point-spread functions and 3D iterative restoration processing to form 3D image stacks. Stacks were then visualized using Volocity to generate the 3D images.

Electron microscopy
-------------------

For electron microscopy, cells were grown to the postdiauxic phase and processed as previously described ([@B21]). For statistically assessing the ER proliferation, the ER was divided into three major subdomains: the nuclear envelope, the cortical ER (the ER adjacent to the plasma membrane), and the cytoplasmic ER (the ER connecting the nuclear envelope with the cortical ER). Three different grids with sections obtained from the same preparations were evaluated. For every grid, the percentage of cells displaying ER proliferation in one of the three subdomains was determined by examining 100 randomly selected cell profiles. We analyzed 300 cells/strain.

Cytosol acidification and glucose starvation
--------------------------------------------

*pma1-007* and the corresponding wild-type strain were grown in SC medium containing 2% glucose and buffered with 50 mM sodium phosphate, pH 7.0, to exponential phase (OD~600~ of ∼0.5), pelleted, and resuspended into SC medium 2% glucose, pH 3.0 (adjusted with HCl), and incubated at 30°C for 1 h. Cells treated with acetate were first grown in SC medium 2% glucose to exponential phase, pelleted, resuspended into SC medium 2% glucose containing 100 mM sodium acetate buffered to pH 4.8 or 7.7, and incubated at 30°C for 1 h. For glucose starvation experiments, cells in exponential phase were washed once with SC medium lacking carbon source, resuspended in the same volume of SC medium lacking carbon source, and incubated at 30°C for the indicated times.

Nem1-Spo7 phosphatase assay
---------------------------

All steps of enzyme purification were performed at 4°C. The protein A--tagged Nem1-Spo7 complex was purified by immunoglobulin G (IgG)--Sepharose affinity chromatography as previously described ([@B57]), with minor modifications. Briefly, the cell extract was prepared by lysis with glass beads using a Biospec Products Mini Bead Beater-16 ([@B33]), and the protein A--tagged Nem1-Spo7 complex was eluted from IgG-Sepharose with 50 mM glycine-HCl (pH 3.0). The acid-eluted enzyme preparation was neutralized with 1 M Tris-HCl (pH 8.0) buffer, and the final preparation contained 160 mM Tris-HCl (pH 8.0), 0.02% Triton X-100, and 20% glycerol. The endogenously phosphorylated Pah1 was purified to near homogeneity from *S. cerevisiae* as described previously ([@B46]). Nem1-Spo7 phosphatase activity was measured by following the shift in the electrophoretic mobility of Pah1 upon SDS--PAGE at 30°C. The reaction contained 15 ng of Pah1, 0.7 ng of Nem1-Spo7 phosphatase, 10 mM MgCl~2~, 0.25 mM Triton X-100, 1 mM dithiothreitol, and 100 mM indicated buffers in a total volume of 50 μl. After 10-min incubation, the reaction product was analyzed by SDS--PAGE, followed by Western blot analysis using anti-Pah1 antibodies.

Labeling and analysis of lipids
-------------------------------

Wild-type (BY4742) and mutant (4Δ, 4Δ *dgk1*Δ, 4Δ *pct1*Δ) strains were grown at 30°C from precultures at an OD of 0.1 for 17 and 19 h, respectively. Steady-state labeling of phospholipids and neutral lipids with ^32^Pi and \[2-^14^C\]acetate, respectively, was performed as described previously ([@B24]). The lipids were extracted by the method of [@B3]). Part of the extract was subjected to one-dimensional (1D) TLC on silica gel 60 plates using the solvent system hexane/diethyl ether/acetic acid (40:10:1) to separate total phospholipids and neutral lipids ([@B26]). The other part of the extract was subjected to 1D TLC on Partisil LK6D silica gel 60 plates using the solvent system chloroform/ethanol/water/triethylamine (30:35:7:35) to separate the phospholipids ([@B64]). The identity of the labeled lipids on TLC plates was confirmed by comparison with standards after exposure to iodine vapor. Radiolabeled lipids were visualized by phosphorimaging and subjected to ImageQuant analysis.

Flow cytometry
--------------

BODIPY quantification by flow cytometry was performed as previously described ([@B18]), with minor modifications. Briefly, cells were fixed for 30 min at room temperature with 3.7% formaldehyde, washed once with phosphate-buffered saline, and incubated with 10 μM BODIPY 493/503 for 10 min at room temperature. Cells were immediately analyzed on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Lipid droplet labeling was measured using the FL-1 detector, and the data were analyzed with FlowJo software, version 9 (Tree Star, Ashland, OR).

β-Galactosidase activity
------------------------

Yeast cells expressing an *INO1-LacZ* reporter (pJH359; [@B40]) in 2% glucose SC medium followed by overnight growth in 2% raffinose SC medium were pelleted and resuspended into SC medium containing 2% galactose. Cells were grown for 7 h at 30°C, and β-galactosidase activity was measured as previously described ([@B53]).
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DAG

:   diacylglycerol

ER

:   endoplasmic reticulum

LD

:   lipid droplet

NVJ

:   nuclear vacuole junction

PA

:   phosphatidate

PC

:   phosphatidylcholine

TAG

:   triacylglycerol.
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